University of Pittsburgh
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
The investigators hypothesize that NR will alleviate mitochondrial dysfunction and restore metabolic homeostasis in the intestinal epithelium in pediatric patients with UC. The purpose of the study are: 1. To establish the feasibility of an Randomized Clinical Trial (RCT) investigating the effects of NR in pediatric patients with UC. 2. To evaluate the effects of Nicotinamide adenine dinucleotide (NAD)+ repletion on intestinal epithelial mitochondrial structure and function in human UC patients. The investigators hypothesize that daily NR supplementation will restore NAD+ levels, enhancing P…
Inclusion Criteria: * Pediatric patients (≤18yo); * Diagnosis of mild to moderate ulcerative colitis as determined by Pediatric Ulcerative Colitis Activity Index (PUCAI) and endoscopic scoring (Mayo) at the time of colonoscopy; * Although the investigators will target newly diagnosed patients (therefore, treatment naïve), patients with established disease will also be enrolled. Exclusion Criteria: * Patients with acute severe ulcerative colitis; * Concurrent gastrointestinal infection (ie. Clostridium difficile, Cytomegalovirus, etc.); * A diagnosis of Crohn's disease; * Indeterminate colit…
The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
Standard of Care
Arctuva estimate
Verify or correct the compensation shown for this listing.